Gastrointestinal (GI) Cancers Symposium 2013 Converage

GI Cancers Symposium 2013

Bevacizumab Plus Capecitabine Demonstrates Benefit for Elderly Patients with Metastatic Colorectal Cancer

Bevacizumab plus capecitabine prolonged progression-free survival (PFS) in elderly patients with metastatic colorectal cancer (mCRC), according to results from the first prospective randomized study to demonstrate a benefit in this population, reported in advance of a presentation during the 10th annual Gastrointestinal Cancers Symposium.

Organ-Sparing Surgery Following Chemoradiation Is Effective in Nonmetastatic Esophageal Cancer

Selective organ-sparing surgery after chemoradiation therapy is an effective treatment for patients with nonmetastatic and resectable esophageal cancer, according to findings from the long-term, multicenter phase 2 Radiation Therapy Oncology Group 0246 trial presented during the 10th annual Gastrointestinal Cancers Symposium on January 25th in San Francisco, CA.

Nab-Paclitaxel Plus Gemcitabine Improves Survival in Metastatic Pancreatic Adenocarcinoma

Weekly nanoparticle albumin-bound (nab)-paclitaxel plus gemcitabine significantly improved survival in patients with metastatic adenocarcinoma of the pancreas compared with gemcitabine alone, results of a global phase 3 trial reported in advance of being presented during the 10th annual Gastrointestinal Cancers Symposium on January 25th in San Francisco, CA.

Next post in GI Cancers Symposium 2013